Jefferies Initiates Coverage on Insmed with “Buy” Rating

Analysts at Jefferies Financial Group have initiated coverage on shares of Insmed (NASDAQ:INSM), assigning a “buy” rating in a report released on Monday. This marks a significant endorsement for the biopharmaceutical company, which focuses on therapies for patients with rare and serious diseases, particularly in the area of difficult-to-treat pulmonary infections.

Several other financial institutions have also provided insights on Insmed’s stock recently. Citigroup reaffirmed an “outperform” rating on December 18, while Mizuho adjusted its price target from $211.00 to $204.00 on February 24, retaining an “outperform” rating. Meanwhile, Rothschild & Co Redburn set an ambitious target price of $263.00 on December 4. In contrast, Wells Fargo & Company lowered its target from $234.00 to $208.00 on February 20, while Truist Financial established a target price of $205.00 on January 12.

Currently, analysts have issued a mix of ratings for Insmed, with three analysts rating the stock as a Strong Buy, nineteen as a Buy, one as a Hold, and one as a Sell. According to data from MarketBeat.com, the consensus rating for Insmed is “Buy,” with an average target price of approximately $207.52.

Recent Earnings Performance

Insmed released its latest quarterly earnings report on February 19, revealing a loss of ($1.54) earnings per share (EPS), which fell short of analysts’ expectations of ($1.07) by ($0.47). The company reported revenues of $263.84 million, slightly below the consensus estimate of $263.97 million. Despite this, the company experienced a remarkable year-on-year revenue increase of 152.6%. A year prior, Insmed had reported an EPS of ($1.32).

Equity analysts anticipate that Insmed will post a loss of ($4.56) EPS for the current year, indicating ongoing challenges as the company navigates its financial landscape.

Insider Transactions and Institutional Activity

In related news, insider Orlov S. Nicole Schaeffer sold 87,290 shares of Insmed on January 2, at an average price of $175.20, totaling approximately $15.29 million. Following this transaction, Schaeffer retained 41,754 shares, valued at around $7.31 million, reflecting a significant decrease in ownership of 67.64%. The transaction was filed with the U.S. Securities and Exchange Commission (SEC).

Additionally, CEO William Lewis sold 19,215 shares on January 12 for a total of $3.25 million, reducing his ownership by 5.89%. In total, insiders have sold 189,651 shares valued at approximately $31.78 million in the last quarter, with corporate insiders holding about 3.00% of the company’s stock.

A number of institutional investors have recently adjusted their stakes in Insmed. CIBC Private Wealth Group LLC increased its position by 42.1% in the third quarter, now owning 179 shares valued at $26,000. Other notable transactions include CoreCap Advisors LLC acquiring a new position valued at approximately $27,000, and SBI Securities Co. Ltd. boosting its stake by 404.9% during the same period.

Insmed, headquartered in Bridgewater, New Jersey, is dedicated to developing therapies that improve clinical outcomes for patients with limited treatment options. Its principal marketed product is ARIKAYCE, an inhaled formulation of the antibiotic amikacin approved by the U.S. Food and Drug Administration.

As Insmed continues to navigate its financial landscape amid evolving market conditions, the support from analysts and institutional investors will be pivotal in shaping its future trajectory.